The Hindu Business Line : Pharmalink buys Lilly’s brand

Eli Lilly has sold off its antibiotic brand – Distaclor (Cefaclor) to Pharmalink, a subsidiary of Quintiles International Corp, for an undisclosed sum. The drug which was being marketed in India by Lilly since 1993 is one of its flagship products, said the Indianapolis headquartered pharma company in a release. “The divestiture happens at a time when we are looking to consolidate our footprints in the area of diabetes, oncology, critical care and bone health an d growth. This divestiture is completely aligned with our global strategy of introducing new and innovative products from Lilly’s strong research pipeline,” said Mr Sandeep Gupta, CMD of the company’s operation in India. —

More Stories on : Mergers & Acquisitions | Retailing | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Vidula Jalan to get Mangalam Timber Products

UK publishing house setting up base in India

Gayatri Projects issues yen bonds

Heritage Foods proposes dividend

As a sector moves from early stage to maturity, PE activity broadens

Pharmalink buys Lilly’s brand

Cranes Soft buys Proland, Caravel

Lumax plans production facility in Thailand

Lenzing, Modi Group in pact for viscose plant

Ansal Properties makes Rs 2,000-cr hospitality foray

Roadmap for Mahindra’s US entry with Scorpio

M&M plans doubling exports every year

Marriott plans expanding base in India

IL&FS plans 4,000 MW power project in TN